NCT02485990 is a Phase 1 clinical trial of Tremelimumab in Primary Peritoneal Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Who is sponsoring NCT02485990?

NCT02485990 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What drugs are being tested in NCT02485990?

Interventions in NCT02485990: Tremelimumab, Olaparib.

What condition does NCT02485990 study?

NCT02485990 studies Primary Peritoneal Carcinoma.

Is NCT02485990 still recruiting?

NCT02485990 is currently terminated. Last updated 12 April 2021.

Last reviewed 2021-04-12 · How we verify

NCT02485990

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

Terminated Phase 1 Last updated 12 April 2021

What this trial tests

Phase 1 trial testing Tremelimumab in Primary Peritoneal Carcinoma in 24 participants. Terminated before completion.

Timeline

8 January 2016

Primary endpoint
5 March 2020

5 March 2020

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	8 January 2016
Primary completion	5 March 2020
Estimated completion	5 March 2020
Sites	1 location across United States

Drugs / interventions tested

Tremelimumab (TREMELIMUMAB) — full drug profile →
Olaparib (olaparib) — full drug profile →

Conditions studied

Primary Peritoneal Carcinoma — all drugs for Primary Peritoneal Carcinoma →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →

Who can join

18 and older, any sex, with Primary Peritoneal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be looking at what dose of tremelimumab and olaparib is safe and effective in patients with persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Peyraud F, Italiano A. · · 2020 · cited 163× · PMID 32526888 · DOI 10.3390/cancers12061502
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
Boussios S, Karihtala P, Moschetta M, Karathanasi A, et al · · 2019 · cited 109× · PMID 31374917 · DOI 10.3390/diagnostics9030087
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Gaillard SL, Secord AA, Monk B. · · 2016 · cited 105× · PMID 27904752 · DOI 10.1186/s40661-016-0033-6
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
Pansy K, Uhl B, Krstic J, Szmyra M, et al · · 2021 · cited 87× · PMID 34948104 · DOI 10.3390/ijms222413311
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.
Evans T, Matulonis U. · · 2017 · cited 78× · PMID 28491146 · DOI 10.1177/1758834016687254
PARP Inhibitors Resistance: Mechanisms and Perspectives.
Giudice E, Gentile M, Salutari V, Ricci C, et al · · 2022 · cited 64× · PMID 35326571 · DOI 10.3390/cancers14061420
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.
Shi C, Qin K, Lin A, Jiang A, et al · · 2022 · cited 60× · PMID 36071479 · DOI 10.1186/s13046-022-02469-0
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.
Maiorano BA, Maiorano MFP, Lorusso D, Maiello E. · · 2021 · cited 60× · PMID 34503248 · DOI 10.3390/cancers13174438

Verify or expand the search:

Other trials of Tremelimumab

Trials testing the same drug.

NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
NCT07391670 — A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durval · Phase 1 · recruiting
NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
NCT07174570 — Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer · Phase 2 · recruiting

Other recruiting trials for Primary Peritoneal Carcinoma

Currently open trials in the same condition.

NCT07480954 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) · Phase 1, PHASE2 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting
NCT07023484 — Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer · Phase 2 · recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials

Trials by the same sponsor.

NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02485990 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 12 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02485990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing